Sanjay Kulkarni
Research & Publications
Biography
News
Research Summary
My current research interests focus on improving public awareness of living donation and identifying outcomes of inactive patients on the organ transplant waitlist. The Center for Living Organ Donors represents a novel care model that is based on the long-term health of prior living donors and leverages donor experience through trained ambassadors who share their stories with the public at large. We aim to improve knowledge of preventative health measures of individuals with chronic disease leading to organ failure, particularly in underserved communities. I work closely with YanHong Deng, MPH, and Geliang Gan, MS from the Yale Center of Analytical Science to use novel multi-state models to study how patients move from inactive to active status and vice versa. The only way a patient can have access to a deceased donor organ is through active status and we hope to improve care coordination of inactive patients to resolve issues that will confer access to transplants.
Specialized Terms: Living donor awareness, disparities in waitlist outcomes
Extensive Research Description
Living kidney donation has been a primary clinical and academic interest in my career. Yale-New Haven Hospitals' novel Center for Living Organ Donors is a care model that provides an opportunity to study how to improve public awareness of living donation. Several studies are underway that focus on improving individual access to living donation (YNHH 15-second connection; https://www.ynhh.org/videos/center-for-living-donors-finding-donor-238) and provide focused education to individuals in underserved communities related to preventive measures that may abrogate the development of end-organ failure.
We have completed a prospective, multi-center study of 307 living kidney donors through a grant from the Greenwall Foundation. The study looks at an individuals' perception of living a donation, their risk tolerance, and if relationship closeness impacts a donor's willingness to take risks. Several publications and international presentations have come from the ongoing research:
1. Thiessen C, Gannon J, Li S, Skrip L, Dobosz D, Gan G, Deng Y, Kennedy C, Gray D, Mussell A, Reese P, Gordon E, Kulkarni S. Quantifying Risk Tolerance Among Potential Living Kidney Donors with the Donation-Specific Risk Questionnaire. American Journal of Kidney Diseases 2021;87(2):246-258.
2. Kulkarni S, Thiessen C, Formica R, Schilsky M, Mulligan D and D’ Aquila R. The long-term follow-up and support for living organ donors: A center-based initiative founded on developing a community of living donors. American Journal of Transplantation 2016;16(12):3385-3391.
3. Thiessen C, Gordon EJ, Reese PP, Kulkarni S. Development of a Donor-Centered Approach to Risk Assessment: Rebalancing Non-maleficence and Autonomy. American Journal of Transplantation 2015;15(9):2314-2323.
4. Thiessen C, Kim YA, Formica R, Bia M and Kulkarni S. Confidentiality and availability of an “alibi” for potential living kidney donors in the United States. Journal of Medical Ethics 2015:41(7):506-510.
Access to transplantation encompasses the referral, listing, and transplant itself. One area that has not been studied extensively is patients who are listed but remain inactive on the waitlist. Approximately a third of all listed patients are inactive, which means they are not eligible to receive deceased donor organ offers. Collaborating with YanHong Deng, MPH, and Geliang Gan, MS from the Yale Center for Analytical Sciences, we have used novel multi-state models to analyze predictors of inactive to active transitions. For kidney transplant patients, there are clear racial disparities in resolving issues of inactive status which we hope will lead to better care coordination between transplant centers, dialysis units, and providers to improve access to transplantation. Our first major publication on the topic was published in JAMASurgery and we are currently working on applying this methodology to the liver transplant waitlist:
Kulkarni S, Ladin K, Haakinson D, Greene E, Geilang G, and Deng Y. Association of Racial Disparity with Access to Kidney Transplant After the Implementation of the New Kidney Allocation System. JAMASurgery 2019;154(7):618-625.
Coauthors
Research Interests
Delivery of Health Care; Kidney; Kidney Failure, Chronic; Liver; Nephrology; Risk; Transplantation; Living Donors
Public Health Interests
Behavioral Health; Health Care Management; Mental Health; Health Equity, Disparities, Social Determinants and Justice; Health Systems Reform
Research Image
Dynamic Prediction of the Impact of Inactive Status Transitions
Selected Publications
- Honoring the gift: The transformative potential of transplant-declined human organsAlbert C, Harris M, DiRito J, Shi A, Edwards C, Harkins L, Lysyy T, Kulkarni S, Mulligan D, Hosgood S, Watson C, Friend P, Nicholson M, Haakinson D, Saeb-Parsy K, Tietjen G. Honoring the gift: The transformative potential of transplant-declined human organs. American Journal Of Transplantation 2023, 23: 165-170. PMID: 36695696, DOI: 10.1016/j.ajt.2022.11.015.
- Honoring the gift: The transformative potential of transplant-declined human organsAlbert C, Harris M, DiRito J, Shi A, Edwards C, Harkins L, Lysyy T, Kulkarni S, Mulligan D, Hosgood S, Watson C, Friend P, Nicholson M, Haakinson D, Saeb-Parsy K, Tietjen G. Honoring the gift: The transformative potential of transplant-declined human organs. American Journal Of Transplantation 2023 DOI: 10.1016/j.ajt.2022.11.015.
- Blood Transcriptomes of SARS-CoV-2–Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to SeveritySun Z, Zhang Z, Banu K, Azzi YA, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Kim Y, Pell J, Tietjen G, Asch W, Kulkarni S, Formica R, Rana M, Maltzman JS, Zhang W, Akalin E, Heeger PS, Cravedi P, Menon MC. Blood Transcriptomes of SARS-CoV-2–Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity. Journal Of The American Society Of Nephrology 2022, 33: 2108-2122. PMID: 36041788, PMCID: PMC9678030, DOI: 10.1681/asn.2022010125.
- Ethical analysis examining the prioritisation of living donor transplantation in times of healthcare rationingKulkarni S, Flescher A, Ahmad M, Bayliss G, Bearl D, Biondi L, Davis E, George R, Gordon E, Lyons T, Wightman A, Ladin K. Ethical analysis examining the prioritisation of living donor transplantation in times of healthcare rationing. Journal Of Medical Ethics 2022, 49: 389-392. PMID: 34983855, PMCID: PMC10314075, DOI: 10.1136/medethics-2021-107574.
- Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplantMerola J, Gan G, Stewart D, Noreen S, Mulligan D, Batra R, Haakinson D, Deng Y, Kulkarni S. Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant. PLOS ONE 2021, 16: e0260000. PMID: 34793524, PMCID: PMC8601542, DOI: 10.1371/journal.pone.0260000.
- Everything has a value, except human lifeOrandi BJ, Kulkarni S. Everything has a value, except human life. Transplant International 2021, 34: 1571-1572. PMID: 34192376, PMCID: PMC8363555, DOI: 10.1111/tri.13966.
- Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States.Azar MM, Cohen E, Ma L, Cissé OH, Gan G, Deng Y, Belfield K, Asch W, Grant M, Gleeson S, Koff A, Gaston DC, Topal J, Curran S, Kulkarni S, Kovacs JA, Malinis M. Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States. Clinical Infectious Diseases 2021, 74: 639-647. PMID: 34017984, PMCID: PMC9012955, DOI: 10.1093/cid/ciab474.
- Living Donor Nephrectomy: Approaches, Innovations, and OutcomesMerola J, Cooper M, Kulkarni S. Living Donor Nephrectomy: Approaches, Innovations, and Outcomes. 2021, 291-302. DOI: 10.1007/978-3-030-53618-3_13.
- Quantifying Risk Tolerance Among Potential Living Kidney Donors With the Donor-Specific Risk QuestionnaireThiessen C, Gannon J, Li S, Skrip L, Dobosz D, Gan G, Deng Y, Kennedy K, Gray D, Mussell A, Reese PP, Gordon EJ, Kulkarni S. Quantifying Risk Tolerance Among Potential Living Kidney Donors With the Donor-Specific Risk Questionnaire. American Journal Of Kidney Diseases 2021, 78: 246-258. PMID: 33508397, DOI: 10.1053/j.ajkd.2020.11.028.
- Leveling-up versus leveling-down to address health disparities in transplantationKulkarni S, Ladin K. Leveling-up versus leveling-down to address health disparities in transplantation. American Journal Of Transplantation 2021, 21: 917-918. PMID: 33326686, PMCID: PMC7986107, DOI: 10.1111/ajt.16458.
- 1099. Opportunistic Infections Among Long Term Survivors of Kidney Transplantation: Defining Risk FactorsCheung H, Azar M, Gan G, Deng Y, Cohen E, Kulkarni S, Malinis M. 1099. Opportunistic Infections Among Long Term Survivors of Kidney Transplantation: Defining Risk Factors. Open Forum Infectious Diseases 2020, 7: s579-s580. PMCID: PMC7776620, DOI: 10.1093/ofid/ofaa439.1285.
- 1110. Very Late Onset Infections Amongst Long Term Survivors of Kidney TransplantationCheung H, Azar M, Gan G, Deng Y, Cohen E, Kulkarni S, Malinis M. 1110. Very Late Onset Infections Amongst Long Term Survivors of Kidney Transplantation. Open Forum Infectious Diseases 2020, 7: s585-s585. PMCID: PMC7777311, DOI: 10.1093/ofid/ofaa439.1296.
- The Development of a Comprehensive Multi-Institutional, Multi-Disciplinary Infrastructure for the Successful Implementation of a Robotic-Assisted Kidney Transplant (RAKT) ProgramHaakinson D, Tzvetanov I, Turner A, Deshpande R, Formica R, Kulkarni S, Benedetti E, Mulligan D. The Development of a Comprehensive Multi-Institutional, Multi-Disciplinary Infrastructure for the Successful Implementation of a Robotic-Assisted Kidney Transplant (RAKT) Program. Journal Of The American College Of Surgeons 2020, 231: e224. DOI: 10.1016/j.jamcollsurg.2020.08.597.
- INACTIVE STATUS CHANGE IS AN INDEPENDENT PREDICTOR OF WAITLIST MORTALITY AND DISPROPORTIONATELY IMPACTS PATIENTS IN DONOR SERVICE AREAS WITH A HIGHER MEDIAN MELD AT TRANSPLANTBatra R, Noreen S, Stewart D, Haakinson D, Gan G, Deng Y, Mulligan D, Kulkarni S. INACTIVE STATUS CHANGE IS AN INDEPENDENT PREDICTOR OF WAITLIST MORTALITY AND DISPROPORTIONATELY IMPACTS PATIENTS IN DONOR SERVICE AREAS WITH A HIGHER MEDIAN MELD AT TRANSPLANT. Transplantation 2020, 104: s213-s213. DOI: 10.1097/01.tp.0000699484.39814.91.
- Reply to “Ethical principles governing organ transplantation apply to paired exchange programs”Ladin K, Kulkarni S. Reply to “Ethical principles governing organ transplantation apply to paired exchange programs”. American Journal Of Transplantation 2020, 20: 1758-1759. PMID: 32337792, DOI: 10.1111/ajt.15945.
- Ethical principles governing organ transplantation apply to paired exchange programsKulkarni S, Ladin K. Ethical principles governing organ transplantation apply to paired exchange programs. American Journal Of Transplantation 2020, 20: 1223-1224. PMID: 32022980, PMCID: PMC7217160, DOI: 10.1111/ajt.15807.
- Deceased donors: Defining drug‐related deathsCmunt K, Danovitch G, Delmonico F, Fynn‐Thompson F, Glazier A, Grandas J, Gunderson S, Jendrisak M, Johnson HK, Kulkarni S, Lipkowitz G, Meyer K, Mulligan D, Nathan H, Mone T, Moritz M, O'Connor K, Payne W, Souter M, Wood RP. Deceased donors: Defining drug‐related deaths. Clinical Transplantation 2020, 34: e13800. PMID: 32077534, DOI: 10.1111/ctr.13800.
- A Pharmacist-Driven Intervention Designed to Improve Medication Accuracy in the Outpatient Kidney Transplant Setting.Cohen EA, McKimmy D, Cerilli A, Kulkarni S. A Pharmacist-Driven Intervention Designed to Improve Medication Accuracy in the Outpatient Kidney Transplant Setting. Drug, Healthcare And Patient Safety 2020, 12: 229-235. PMID: 33269008, PMCID: PMC7701366, DOI: 10.2147/DHPS.S264022.
- Outcomes From Right Versus Left Deceased-Donor Kidney Transplants: A US National Cohort StudyKulkarni S, Wei G, Jiang W, Lopez LA, Parikh CR, Hall IE. Outcomes From Right Versus Left Deceased-Donor Kidney Transplants: A US National Cohort Study. American Journal Of Kidney Diseases 2019, 75: 725-735. PMID: 31812448, PMCID: PMC7288694, DOI: 10.1053/j.ajkd.2019.08.018.
- Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trialsSchröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials. American Journal Of Transplantation 2019, 20: 564-572. PMID: 31452319, DOI: 10.1111/ajt.15580.
- Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation SystemKulkarni S, Ladin K, Haakinson D, Greene E, Li L, Deng Y. Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System. JAMA Surgery 2019, 154: 618-625. PMID: 30942882, PMCID: PMC6583835, DOI: 10.1001/jamasurg.2019.0512.
- Building Local Communities of Prior Living Donors and Creating a Social Architecture to Improve Rates of Living Kidney DonationKulkarni S, Yoo P, Batra R, Haakinson D, Schulam P, Mulligan D. Building Local Communities of Prior Living Donors and Creating a Social Architecture to Improve Rates of Living Kidney Donation. Journal Of The American College Of Surgeons 2018, 227: e29. DOI: 10.1016/j.jamcollsurg.2018.08.074.
- Ongoing Disparities in Access to Kidney Transplantation in the Post-Kidney Allocation System EraKulkarni S, Ladin K, Greene E, Li L, Deng Y. Ongoing Disparities in Access to Kidney Transplantation in the Post-Kidney Allocation System Era. Journal Of The American College Of Surgeons 2018, 227: e60. DOI: 10.1016/j.jamcollsurg.2018.08.155.
- How Potential Living Kidney Donors View End-Stage Renal Disease Risk: A Longitudinal, Multi-Center StudyThiessen C, Gannon J, Gray D, Kennedy K, Dobosz D, Li S, Mussell A, Gordon E, Reese P, Kulkarni S. How Potential Living Kidney Donors View End-Stage Renal Disease Risk: A Longitudinal, Multi-Center Study. Journal Of The American College Of Surgeons 2018, 227: s91. DOI: 10.1016/j.jamcollsurg.2018.07.181.
- Opting Out and Offers of ‘Alibis’ for Potential Living Kidney Donors in US Transplant CentersIskander R, Kulkarni S, Thiessen C. Opting Out and Offers of ‘Alibis’ for Potential Living Kidney Donors in US Transplant Centers. Transplantation 2018, 102: s243. DOI: 10.1097/01.tp.0000542922.79287.57.
- Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney TransplantMcCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, Kulkarni S, Esnaola G, Shults J, Thiessen C, Reese PP. Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation 2018, 102: e163-e170. PMID: 29346260, DOI: 10.1097/tp.0000000000002099.
- The Psychosocial Impact of Withdrawing from Living Kidney DonationThiessen C, Kulkarni S. The Psychosocial Impact of Withdrawing from Living Kidney Donation. Current Transplantation Reports 2018, 5: 64-71. DOI: 10.1007/s40472-018-0185-x.
- Robotic Assisted Kidney Transplant, Reserved for the DeservedBatra R, Mulligan D, Kulkarni S, Bhati C. Robotic Assisted Kidney Transplant, Reserved for the Deserved. Journal Of Clinical And Experimental Transplantation 2018, 3: 1-3. DOI: 10.4172/2475-7640.1000e104.
- Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modelingKulkarni S, Hall I, Formica R, Thiessen C, Stewart D, Gan G, Greene E, Deng Y. Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modeling. PLOS ONE 2017, 12: e0190277. PMID: 29287087, PMCID: PMC5747475, DOI: 10.1371/journal.pone.0190277.
- Assessing Living Donor Priorities Through Nominal Group TechniqueDorflinger LM, Kulkarni S, Thiessen C, Klarman S, Fraenkel L. Assessing Living Donor Priorities Through Nominal Group Technique. Progress In Transplantation 2017, 28: 29-35. PMID: 29243533, PMCID: PMC5735019, DOI: 10.1177/1526924817746682.
- Being Thoughtful about DesensitizationFormica RN, Kulkarni S. Being Thoughtful about Desensitization. Clinical Journal Of The American Society Of Nephrology 2017, 12: 1878-1880. PMID: 28974523, PMCID: PMC5672977, DOI: 10.2215/cjn.09000817.
- Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in the era of donor shortageChoe J, Merola J, Kulkarni S, Mulligan DC. Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in the era of donor shortage. Clinical Transplantation 2017, 31 PMID: 28643333, DOI: 10.1111/ctr.13022.
- Opting out: a single-centre pilot study assessing the reasons for and the psychosocial impact of withdrawing from living kidney donor evaluationThiessen C, Jaji Z, Joyce M, Zimbrean P, Reese P, Gordon EJ, Kulkarni S. Opting out: a single-centre pilot study assessing the reasons for and the psychosocial impact of withdrawing from living kidney donor evaluation. Journal Of Medical Ethics 2017, 43: 756. PMID: 28258071, DOI: 10.1136/medethics-2016-103512.
- A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney TransplantationKulkarni S, Do A, Liapakis A. A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation. Internal Medicine Review 2017, 3 DOI: 10.18103/imr.v3i9.570.
- A Call for Research on Individuals Who Opt Out of Living Kidney DonationThiessen C, Kulkarni S, Reese PP, Gordon EJ. A Call for Research on Individuals Who Opt Out of Living Kidney Donation. Transplantation 2016, 100: 2527-2532. PMID: 27495760, DOI: 10.1097/tp.0000000000001408.
- Parathyroidectomy prior to kidney transplant decreases graft failureCallender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, Kulkarni S. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery 2016, 161: 44-50. PMID: 27863776, DOI: 10.1016/j.surg.2016.10.003.
- Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case ReportMerola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, Kulkarni S. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. Transplantation Proceedings 2016, 48: 3106-3108. PMID: 27932157, DOI: 10.1016/j.transproceed.2016.04.005.
- Perioperative outcomes of coronary artery bypass graft in renal transplant recipients in the United States: results from the Nationwide Inpatient SampleTooley JE, Bohl DD, Kulkarni S, Rodriguez‐Davalos M, Mangi A, Mulligan DC, Yoo PS. Perioperative outcomes of coronary artery bypass graft in renal transplant recipients in the United States: results from the Nationwide Inpatient Sample. Clinical Transplantation 2016, 30: 1258-1263. PMID: 27440000, DOI: 10.1111/ctr.12816.
- Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled TrialKulkarni S, Kirkiles-Smith N, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.
- The Long-Term Follow-up and Support for Living Organ Donors: A Center-Based Initiative Founded on Developing a Community of Living DonorsKulkarni S, Thiessen C, Formica RN, Schilsky M, Mulligan D, D'Aquila R. The Long-Term Follow-up and Support for Living Organ Donors: A Center-Based Initiative Founded on Developing a Community of Living Donors. American Journal Of Transplantation 2016, 16: 3385-3391. PMID: 27500361, DOI: 10.1111/ajt.14005.
- De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant RecipientCohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.
- Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized TrialRostaing L, Bunnapradist S, Grinyó J, Ciechanowski K, Denny J, Silva H, Budde K, Group E, Denny J, Kulkarni S, Hricik D, Bresnahan B, Bunnapradist S, El-Sabrout R, Chan L, Ciancio G, El-Ghoroury M, Goldstein M, Gaston R, Gohh R, Killackey M, King A, Knight R, Kore A, Sudan D, Friedmann J, Mulgaonkar S, Nolan C, Pankewycz O, Pirsch J, Schaefer H, Steinberg S, Gelb B, True K, West-Thielke P, Waybill M, Wolf J, Ketel B, Harland R, Shihab F, Cassuto E, Le Meur Y, Rostaing L, Mariat C, Grinyó J, Puig J, Seron D, Tisone G, Ciechanowski K, Foroncewicz B, Wlodarczyk Z, Budde K, Witzke O, Mondragon G, Urrea E, Gomez J, Acevedo R, del Carmen Rial M, Novoa P, Silva H, Garcia V, Carvalho D, Saber L, Contieri F, Bastos M, Manfro R, Kanellis J, Eris J, O’Connell P, Hughes P, Russ G, Pidgeon G, Dittmer I, Kee T, Vathsala A, Naumovic R, Mitic I, Parmjeet R. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal Of Kidney Diseases 2015, 67: 648-659. PMID: 26717860, DOI: 10.1053/j.ajkd.2015.10.024.
- Duration of Prophylaxis against Fungal Infection in Kidney Transplant RecipientsGuerra CM, Formica RN, Kulkarni S, Asch WS, Tichy EM. Duration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients. Progress In Transplantation 2015, 25: 311-315. PMID: 26645924, DOI: 10.7182/pit2015929.
- The Stanford Integrated Psychosocial Assessment for transplantation, healthcare utilization, and adverse medical events for 3years post-kidney transplantationZimbrean P, Patron-Lozano, Edgington N, Joyce M, Gaffney C, Skrip L, Wang J, Kulkarni S. The Stanford Integrated Psychosocial Assessment for transplantation, healthcare utilization, and adverse medical events for 3years post-kidney transplantation. Journal Of Psychosomatic Research 2015, 78: 634. DOI: 10.1016/j.jpsychores.2015.03.149.
- Psychiatric and medical adverse events for kidney transplant recipients with lithium induced kidney diseaseZimbrean P, Formica R, Ash W, Lettieri D, Kulkarni S. Psychiatric and medical adverse events for kidney transplant recipients with lithium induced kidney disease. Journal Of Psychosomatic Research 2015, 78: 634. DOI: 10.1016/j.jpsychores.2015.03.148.
- Development of a Donor-Centered Approach to Risk Assessment: Rebalancing Nonmaleficence and AutonomyThiessen C, Gordon EJ, Reese PP, Kulkarni S. Development of a Donor-Centered Approach to Risk Assessment: Rebalancing Nonmaleficence and Autonomy. American Journal Of Transplantation 2015, 15: 2314-2323. PMID: 25868787, DOI: 10.1111/ajt.13272.
- Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational CohortDo A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort. Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.
- Opting out: confidentiality and availability of an ‘alibi’ for potential living kidney donors in the USAThiessen C, Kim YA, Formica R, Bia M, Kulkarni S. Opting out: confidentiality and availability of an ‘alibi’ for potential living kidney donors in the USA. Journal Of Medical Ethics 2014, 41: 506. PMID: 25368413, DOI: 10.1136/medethics-2014-102184.
- Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiologyVilarinho S, Choi M, Jain D, Malhotra A, Kulkarni S, Pashankar D, Phatak U, Patel M, Bale A, Mane S, Lifton RP, Mistry PK. Individual exome analysis in diagnosis and management of paediatric liver failure of indeterminate aetiology. Journal Of Hepatology 2014, 61: 1056-1063. PMID: 25016221, PMCID: PMC4203706, DOI: 10.1016/j.jhep.2014.06.038.
- Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment.Kulkarni S, Nancy K, Formica R, Moeckel G, Pober J. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment. Transplantation 2014, 98: 79. DOI: 10.1097/00007890-201407151-00247.
- The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation.Thiessen C, PatronLozano R, Edgington N, Joyce M, Gaffney C, Skrip L, Wang J, Zimbrean P, Kulkarni S. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation. Transplantation 2014, 98: 576. DOI: 10.1097/00007890-201407151-01938.
- Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offersThiessen C, Kim YA, Yoo PS, Rodriguez‐Davalos M, Mulligan D, Kulkarni S. Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers. Liver Transplantation 2014, 20: 416-424. PMID: 24415564, DOI: 10.1002/lt.23822.
- Segmental Grafts in Adult and Pediatric Liver Transplantation: Improving Outcomes by Minimizing Vascular ComplicationsRodriguez-Davalos MI, Arvelakis A, Umman V, Tanjavur V, Yoo PS, Kulkarni S, Luczycki SM, Schilsky M, Emre S. Segmental Grafts in Adult and Pediatric Liver Transplantation: Improving Outcomes by Minimizing Vascular Complications. JAMA Surgery 2014, 149: 63-70. PMID: 24284803, DOI: 10.1001/jamasurg.2013.3384.
- CT angiography in potential living kidney donors: 80 kVp versus 120 kVp.Davarpanah AH, Pahade JK, Cornfeld D, Ghita M, Kulkarni S, Israel GM. CT angiography in potential living kidney donors: 80 kVp versus 120 kVp. American Journal Of Roentgenology 2013, 201: w753-60. PMID: 24147505, DOI: 10.2214/ajr.12.10439.
- Alloantibody and Complement Promote T Cell–Mediated Cardiac Allograft Vasculopathy Through Noncanonical Nuclear Factor-&kgr;B Signaling in Endothelial CellsJane-wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, Abrahimi P, Devalliere J, Moeckel G, Kulkarni S, Tellides G, Pober JS. Alloantibody and Complement Promote T Cell–Mediated Cardiac Allograft Vasculopathy Through Noncanonical Nuclear Factor-&kgr;B Signaling in Endothelial Cells. Circulation 2013, 128: 2504-2516. PMID: 24045046, PMCID: PMC3885874, DOI: 10.1161/circulationaha.113.002972.
- Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN RequirementsThiessen C, Kim YA, Formica R, Bia M, Kulkarni S. Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN Requirements. American Journal Of Transplantation 2013, 13: 2713-2721. PMID: 24020884, DOI: 10.1111/ajt.12406.
- Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipientsHeavner MS, Tichy EM, Yazdi M, Formica RN, Kulkarni S, Emre S. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. American Journal Of Health-System Pharmacy 2013, 70: 1507-1512. PMID: 23943182, DOI: 10.2146/ajhp120783.
- Anatomic Considerations in the Surgical Resection of Hepatocellular CarcinomaYoo PS, Enestvedt CK, Kulkarni S. Anatomic Considerations in the Surgical Resection of Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2013, 47: s11-s15. PMID: 23632343, DOI: 10.1097/mcg.0b013e318280ce5f.
- Retrocaval Renal Artery Bifurcation Is Not a Contraindication to Laparoscopic Right Donor NephrectomyGandelman JA, Yoo PS, Kulkarni S. Retrocaval Renal Artery Bifurcation Is Not a Contraindication to Laparoscopic Right Donor Nephrectomy. Journal Of The American College Of Surgeons 2013, 217: 406-411. PMID: 23791562, DOI: 10.1016/j.jamcollsurg.2013.03.026.
- Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cellsWang C, Yi T, Qin L, Maldonado RA, von Andrian UH, Kulkarni S, Tellides G, Pober JS. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Journal Of Clinical Investigation 2013, 123: 1677-1693. PMID: 23478407, PMCID: PMC3613923, DOI: 10.1172/jci66204.
- Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survivalGuo X, Schmitz JC, Kenney BC, Uchio EM, Kulkarni S, Cha CH. Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survival. Cancer Science 2012, 103: 1474-1480. PMID: 22625651, PMCID: PMC7659195, DOI: 10.1111/j.1349-7006.2012.02341.x.
- Complication Arising from a Duplicated Inferior Vena Cava following Laparoscopic Living Donor Nephrectomy: A Case ReportChristakis P, Cimsit B, Kulkarni S. Complication Arising from a Duplicated Inferior Vena Cava following Laparoscopic Living Donor Nephrectomy: A Case Report. Transplantation Proceedings 2012, 44: 1450-1452. PMID: 22664034, DOI: 10.1016/j.transproceed.2011.11.064.
- A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement ReportFormica RN, Barrantes F, Asch WS, Bia MJ, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Kulkarni S. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. American Journal Of Kidney Diseases 2012, 60: 288-294. PMID: 22571868, DOI: 10.1053/j.ajkd.2012.04.008.
- Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T CellsFogal B, Yi T, Wang C, Rao DA, Lebastchi A, Kulkarni S, Tellides G, Pober JS. Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells. The Journal Of Immunology 2011, 187: 6268-6280. PMID: 22084439, PMCID: PMC3237826, DOI: 10.4049/jimmunol.1003774.
- Reperfusion Injury Intensifies the Adaptive Human T Cell Alloresponse in a Human-Mouse Chimeric Artery ModelYi T, Fogal B, Hao Z, Tobiasova Z, Wang C, Rao DA, Al-Lamki RS, Kirkiles-Smith NC, Kulkarni S, Bradley JR, Bothwell AL, Sessa WC, Tellides G, Pober JS. Reperfusion Injury Intensifies the Adaptive Human T Cell Alloresponse in a Human-Mouse Chimeric Artery Model. Arteriosclerosis Thrombosis And Vascular Biology 2011, 32: 353-360. PMID: 22053072, PMCID: PMC3262100, DOI: 10.1161/atvbaha.111.239285.
- Laparoscopic repair of iatrogenic diaphragmatic hernia following radiofrequency ablation for hepatocellular carcinomaSingh M, Singh G, Pandey A, Cha CH, Kulkarni S. Laparoscopic repair of iatrogenic diaphragmatic hernia following radiofrequency ablation for hepatocellular carcinoma. Hepatology Research 2011, 41: 1132-1136. PMID: 22032681, DOI: 10.1111/j.1872-034x.2011.00865.x.
- When should a hepatitis C‐positive ESRD patient receive a renal transplant?Kulkarni S, Taddei TH. When should a hepatitis C‐positive ESRD patient receive a renal transplant? Seminars In Dialysis 2011, 24: 438-439. PMID: 21801216, DOI: 10.1111/j.1525-139x.2011.00898.x.
- Peroxisome Proliferator–Activated Receptor-γ Agonists Prevent In Vivo Remodeling of Human Artery Induced by Alloreactive T CellsTobiasova Z, Zhang L, Yi T, Qin L, Manes TD, Kulkarni S, Lorber MI, Rodriguez FC, Choi JM, Tellides G, Pober JS, Kawikova I, Bothwell AL. Peroxisome Proliferator–Activated Receptor-γ Agonists Prevent In Vivo Remodeling of Human Artery Induced by Alloreactive T Cells. Circulation 2011, 124: 196-205. PMID: 21690493, PMCID: PMC3347886, DOI: 10.1161/circulationaha.110.015396.
- Abstract 5149: Intermedin stimulates cell growth, migration, and angiogenesis in human colorectal adenocarcinoma and hepatocellular carcinomaGuo X, Schmitz J, Uchio E, Kenney B, Kulkarni S, Cha C. Abstract 5149: Intermedin stimulates cell growth, migration, and angiogenesis in human colorectal adenocarcinoma and hepatocellular carcinoma. Cancer Research 2011, 71: 5149-5149. DOI: 10.1158/1538-7445.am2011-5149.
- Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center ExperienceCimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, Asch W, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. PMID: 21486624, DOI: 10.1016/j.transproceed.2011.02.033.
- Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver TransplantationCimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
- Pediatric Liver Transplantation for Inherited Metabolic Liver Disease: A Single-Center ExperienceRosencrantz R, Cimsit B, Seashore M, Arvelakis A, Kulkarni S, Ghiroli M, Emre S. Pediatric Liver Transplantation for Inherited Metabolic Liver Disease: A Single-Center Experience. Transplantation Proceedings 2011, 43: 896-900. PMID: 21486623, DOI: 10.1016/j.transproceed.2011.02.035.
- Multidetector CT angiography in living donor renal transplantation: accuracy and discrepancies in right venous anatomyKulkarni S, Emre S, Arvelakis A, Asch W, Bia M, Formica R, Israel G. Multidetector CT angiography in living donor renal transplantation: accuracy and discrepancies in right venous anatomy. Clinical Transplantation 2011, 25: 77-82. PMID: 20070320, DOI: 10.1111/j.1399-0012.2009.01193.x.
- Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literatureCuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.
- Accepting a donor kidney: an evaluation of patients’ and transplant surgeons’ prioritiesSolomon DA, Rabidou N, Kulkarni S, Formica R, Fraenkel L. Accepting a donor kidney: an evaluation of patients’ and transplant surgeons’ priorities. Clinical Transplantation 2010, 25: 786-793. PMID: 20964716, PMCID: PMC4846340, DOI: 10.1111/j.1399-0012.2010.01342.x.
- KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsBia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal Of Kidney Diseases 2010, 56: 189-218. PMID: 20598411, DOI: 10.1053/j.ajkd.2010.04.010.
- A CENTER COORDINATED, PRE-TRANSPLANT EVALUATION ELIMINATES BARRIERS TO KIDNEY TRANSPLANTATION AND ESTABLISHES PARITY ACROSS ALL SOCIO-ECONOMIC GROUPSBarrantes F, Arvelakis A, Asch W, Coca S, Kalyesubula R, Bia M, Formica R, Kulkarni S. A CENTER COORDINATED, PRE-TRANSPLANT EVALUATION ELIMINATES BARRIERS TO KIDNEY TRANSPLANTATION AND ESTABLISHES PARITY ACROSS ALL SOCIO-ECONOMIC GROUPS. Transplantation 2010, 90: 249. DOI: 10.1097/00007890-201007272-00471.
- OUTCOMES OF DONOR EVALUATIONS FOR LIVING DONOR LIVER TRANSPLANTATION (LDLT); WHO IS THE IDEAL DONOR? IS THERE ROOM FOR IMPROVEMENT?Arvelakis A, Kulkarni S, Emre S. OUTCOMES OF DONOR EVALUATIONS FOR LIVING DONOR LIVER TRANSPLANTATION (LDLT); WHO IS THE IDEAL DONOR? IS THERE ROOM FOR IMPROVEMENT? Transplantation 2010, 90: 75. DOI: 10.1097/00007890-201007272-00143.
- Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literatureCaldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, Kulkarni S, Emre S. Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transplantation 2010, 16: 818-826. PMID: 20583082, DOI: 10.1002/lt.22077.
- Significant Sirolimus and Dronedarone Interaction in a Kidney Transplant RecipientTichy EM, Medwid AJ, Mills EA, Formica RN, Kulkarni S. Significant Sirolimus and Dronedarone Interaction in a Kidney Transplant Recipient. Annals Of Pharmacotherapy 2010, 44: 1338-1341. PMID: 20484171, DOI: 10.1345/aph.1p114.
- 45: Single-Day Work-Up Protocol Is Associated With a Shorter Time to Kidney Transplant: The Yale-New Haven Transplantation Center ExperienceBarrantes F, Kalyesubula R, A A, Lettieri D, Asch W, Bia M, Formica R, Kulkarni S. 45: Single-Day Work-Up Protocol Is Associated With a Shorter Time to Kidney Transplant: The Yale-New Haven Transplantation Center Experience. American Journal Of Kidney Diseases 2010, 55: b43. DOI: 10.1053/j.ajkd.2010.02.052.
- Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information?Formica RN, Asch WS, Wagner KR, Kulkarni S. Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information? Clinical Journal Of The American Society Of Nephrology 2010, 5: 924-928. PMID: 20203162, PMCID: PMC2863980, DOI: 10.2215/cjn.06820909.
- HuR protein downregulation as an antitumor strategyKiang S, Gao W, Yoo P, Schmitz J, Chu E, Uchio E, Kulkarni S, Cha C. HuR protein downregulation as an antitumor strategy. Journal Of The American College Of Surgeons 2008, 207: s96. DOI: 10.1016/j.jamcollsurg.2008.06.242.
- Living kidney donor informed consent practices vary between US and non-US centersParekh AM, Gordon EJ, Garg AX, Waterman AD, Kulkarni S, Parikh CR. Living kidney donor informed consent practices vary between US and non-US centers. Nephrology Dialysis Transplantation 2008, 23: 3316-3324. PMID: 18599559, PMCID: PMC2720811, DOI: 10.1093/ndt/gfn295.
- Medication Errors in the Outpatient Setting: Classification and Root Cause AnalysisFriedman AL, Geoghegan SR, Sowers NM, Kulkarni S, Formica RN. Medication Errors in the Outpatient Setting: Classification and Root Cause Analysis. JAMA Surgery 2007, 142: 278-283. PMID: 17372053, DOI: 10.1001/archsurg.142.3.278.
- Ethics in Liver TransplantationKulkarni S, Cronin D. Ethics in Liver Transplantation. Seminars In Liver Disease 2006, 26: 234-238. PMID: 16850372, DOI: 10.1055/s-2006-947299.
- UROLOGIC ISSUES AMONG GERIATRIC MEN CONSIDERING RENAL TRANSPLANTATION (TXP).Friedman A, Fox L, Formica R, Kulkarni S, Singh D, Smith D, Eisen T, Bia M, Lorber M. UROLOGIC ISSUES AMONG GERIATRIC MEN CONSIDERING RENAL TRANSPLANTATION (TXP). Transplantation 2006, 82: 450. DOI: 10.1097/00007890-200607152-01153.
- Living donor liver transplantation for pediatric and adult recipientsKulkarni S, Malagò M, Cronin DC. Living donor liver transplantation for pediatric and adult recipients. Nature Reviews Gastroenterology & Hepatology 2006, 3: 149-157. PMID: 16511549, DOI: 10.1038/ncpgasthep0437.
- Ethical tensions in solid organ transplantation: the price of success.Kulkarni S, Cronin DC. Ethical tensions in solid organ transplantation: the price of success. World Journal Of Gastroenterology 2006, 12: 3259-64. PMID: 16718849, PMCID: PMC4087972, DOI: 10.3748/wjg.v12.i20.3259.
- The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experienceSchaffer RL, Kulkarni S, Harper A, Millis JM, Cronin DC. The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experience. Liver Transplantation 2003, 9: 1211-1215. PMID: 14586883, DOI: 10.1053/jlts.2003.50192.
- Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsisKulkarni S, Naureckas E, Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003, 75: 899-901. PMID: 12660522, DOI: 10.1097/01.tp.0000054842.34916.e8.
- EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESION, THREE-YEAR FOLLOW-UP.Buell J, Kulkarni S, Grewal H, Kopelan A, Yoshida A, Swanson A, Cronin D, Bruce D, Newell K, Thistlethwaite J, Woodle E. EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESION, THREE-YEAR FOLLOW-UP. Transplantation 2000, 69: s134. DOI: 10.1097/00007890-200004271-00088.
- IMPACT OF CHANGES TO PEDIATRIC LIVER TRANSPLANT LISTING CRITERIA IN A LARGE REFERAL CENTER.Buell J, Te C, Gupta P, Rivera O, Davis B, Kulkarni S, Yoshida A, Kelly S, Brady L, Cronin D, Millis J. IMPACT OF CHANGES TO PEDIATRIC LIVER TRANSPLANT LISTING CRITERIA IN A LARGE REFERAL CENTER. Transplantation 2000, 69: s369. DOI: 10.1097/00007890-200004271-00990.
- PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENEKulkarni S, Holman P, Kopelan A, van Seventer G, van Seventer J, Kranz D, Woodle E. PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENE. Transplantation 2000, 69: 1209-1217. PMID: 10762228, DOI: 10.1097/00007890-200003270-00028.
- Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experienceWoodle E, Buell J, Siegel C, Kulkarni S, Kopelan A, Grewal H. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. Transplantation Proceedings 1999, 31: 84-85. PMID: 10576053, DOI: 10.1016/s0041-1345(99)00803-9.
- EARLY CORTICOSTEROID WITHDRAWAL WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNO-SUPPRESSION IN RENAL TRANSPLANTATION: EIGHTEEN-MONTH FOLLOW-UPBUELL J, GREWAL H, KRISTO B, KOPELAN A, KULKARNI S, YOSHIDA A, KIM E, SIEGEL C, CRONIN D, BRUCE D, NEWELL K, MILLIS J, THISTLETHWAITE J, WOODLE E. EARLY CORTICOSTEROID WITHDRAWAL WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNO-SUPPRESSION IN RENAL TRANSPLANTATION: EIGHTEEN-MONTH FOLLOW-UP. Transplantation 1999, 67: s545. DOI: 10.1097/00007890-199905150-00037.
- AFRICAN-AMERICAN COMPARED TO CAUCASIAN RESPONSE TO CORTICOSTEROID WITHDRAWAL FOLLOWING TACROLIMUS THERAPY FOR REFRACTORY RENAL REJECTIONBuell J, Mead J, Yoshida A, Kulkarni S, Kristo B, Kim E, Siegel C, Fisher J, Turner C, Bruce D, Cronin D, Millis J, Thistlethwaite J, Bruce D, Woodle E. AFRICAN-AMERICAN COMPARED TO CAUCASIAN RESPONSE TO CORTICOSTEROID WITHDRAWAL FOLLOWING TACROLIMUS THERAPY FOR REFRACTORY RENAL REJECTION. Transplantation 1999, 67: s163. DOI: 10.1097/00007890-199904150-00650.
- PROGRAMMED CELL DEATHWoodle E, Kulkarni S. PROGRAMMED CELL DEATH. Transplantation 1998, 66: 681-691. PMID: 9771830, DOI: 10.1097/00007890-199809270-00001.
- Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex 11E.S.W. supported by NIH Grant# Po1-AI129531-07.Kulkarni S, Holman P, Kranz D, Zhou N, Van Seventer J, Woodle E. Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex 11E.S.W. supported by NIH Grant# Po1-AI129531-07. Transplantation Proceedings 1998, 30: 1081. PMID: 9636438, DOI: 10.1016/s0041-1345(98)00160-2.
- Anti-Human Class I α3 Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC TransgenesWoodle E, Kulkarni S, Zhou N. Anti-Human Class I α3 Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes. Transplantation Proceedings 1998, 30: 1059-1060. PMID: 9636428, DOI: 10.1016/s0041-1345(98)00150-x.
- A MURINE TRANSGENIC MODEL OF HUMAN CLASS I MHC-MEDIATED PROGRAMMED CELL DEATHWoodle E, Kulkarni S, Zhou N. A MURINE TRANSGENIC MODEL OF HUMAN CLASS I MHC-MEDIATED PROGRAMMED CELL DEATH. Transplantation 1998, 65: s96. DOI: 10.1097/00007890-199806270-00395.
- EXPRESSION OF A GPI-ANCHORED, SINGLE-CHAIN ANTIBODY SPECIFIC FOR A CELL DEATH SIGNALING DOMAIN OF HUMAN CLASS I MHCKulkarni S, Van Seventer J, Zhou N, Holman P, Kranz D, Woodle E. EXPRESSION OF A GPI-ANCHORED, SINGLE-CHAIN ANTIBODY SPECIFIC FOR A CELL DEATH SIGNALING DOMAIN OF HUMAN CLASS I MHC. Transplantation 1998, 65: 122. DOI: 10.1097/00007890-199805131-00173.
- A MURINE TRANSGENIC MODEL OF HUMAN CLASS I MHC-MEDIATED PROGRAMMED CELL DEATHWoodle E, Kulkarni S, Zhou N. A MURINE TRANSGENIC MODEL OF HUMAN CLASS I MHC-MEDIATED PROGRAMMED CELL DEATH. Transplantation 1998, 65: 172. DOI: 10.1097/00007890-199805131-00374.
- Expression of human recombinant beta 2-microglobulin by Aspergillus nidulans and its activity.O'Herrin SM, Kulkarni S, Kenealy WR, Fechner JH, Sollinger H, Schneck JP, Burlingham WJ. Expression of human recombinant beta 2-microglobulin by Aspergillus nidulans and its activity. Human Immunology 1996, 51: 63-72. PMID: 8960907.